Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Mar 9;8:4305. doi: 10.1038/s41598-018-22364-z

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2018

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

B49Mod1 inhibits homotypic and heterotypic adhesion of cancer cells specifically. (A) Adherence of U937 monocytes to 4T1 shControl (shCTL, no background) or shBST-2 (blue background) monolayers that were pre-treated with Vehicle or B49Mod1 for 4 hours at 200 ng/well before addition of incoming cells. (B) Adherence of 4T1 shControl (no background) or shBST-2 (blue background) cancer cells to fibronectin-coated plates. Incoming cancer cells were pre-treated with vehicle or B49Mod1 for 2 hours prior to addition to fibronectin-coated plates. (C) Adherence of 4T1 shControl (no background) or shBST-2 (blue background) cancer cells to fibronectin-coated plates that were pre-treated with 200 ng/well of B49Mod1 for 4 hours and washed once before addition of incoming 4T1 cancer cells. (D) Adherence of 4T1 shControl, 4T1 shBST-2, U937 monocytes or SUP-T1 T cells to B49Mod1-coated plates. (E) Adherence of U937 monocytes and SUP-T1 T cells to fibronectin-coated plates. Incoming immune cells were pre-treated with vehicle or B49Mod1 for 2 hours prior to addition to fibronectin-coated plates. (F) Adherence of 4T1 shControl (no background) or shBST-2 (blue background) cancer cells to 4T1 shControl monolayers. In coming cancer cells were pre-treated with vehicle or B49Mod1 for 2 hours prior to addition to 4T1 shControl monolayers. (G) Adherence of U937 monocytes or SUP-T1 T cells to 4T1 shControl monolayers. In coming immune cells were pre-treated with vehicle or B49Mod1 for 2 hours prior to addition to 4T1 shControl monolayers. Error bars correspond to SEM. Significance was taken at *P < 0.05, ***P < 0.001 and ****P < 0.0001. ns = not significant.